| Literature DB >> 35806877 |
Giovanni Maria Garbarino1, Giovanni Guglielmo Laracca1, Alessio Lucarini1, Gianmarco Piccolino1, Paolo Mercantini1, Alessandro Costa2, Giuseppe Tonini3, Giulia Canali1, Edoardo Maria Muttillo1, Gianluca Costa4.
Abstract
BACKGROUND: The advantages of a laparoscopic approach for the treatment of gastric cancer have already been demonstrated in Eastern Countries. This review and meta-analysis aims to merge all the western studies comparing laparoscopic (LG) versus open gastrectomies (OG) to provide pooled results and higher levels of evidence.Entities:
Keywords: West; Western; gastric cancer; laparoscopic gastrectomy; laparoscopic surgery; laparoscopy; open gastrectomy
Year: 2022 PMID: 35806877 PMCID: PMC9267365 DOI: 10.3390/jcm11133590
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.964
Figure 1PRISMA flowchart.
Baseline characteristics of studies included in the meta-analysis.
| Author Year | Country | Study Period | Study Design | Tumor Stage | Extent of Resection | Sample Size | Age | M/F | Follow-Up (Months) | Newcastle-Ottawa Score | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LG | OG | LG | OG | LG | OG | LG | OG | |||||||
| Weber et al., 2003 [ | USA | 1997–2000 | Retrospective comparative | EGC, AGC | SG | 12 | 13 | 67 | 67 | ns | ns | 18 | 18 | 7 |
| Dulucq et al., 2005 [ | France | 1995–2004 | Prospective comparative | EGC, AGC | SG | 16 | 17 | 71 | 70 | 7/9 | 7/10 | ns | ns | 8 |
| TG | 8 | 11 | 75 | 67 | 3/5 | 5/6 | ||||||||
| Huscher et al., 2005 [ | Italy | 1992–1996 | Randomized trial | EGC, AGC | SG | 30 | 29 | 63.2 | 63.6 | 18/12 | 21/8 | 52.2 | 49.7 | 2 * |
| Pugliese et al., 2007 [ | Italy | 2000–2005 | Retrospective comparative | EGC, AGC | SG, TG | 48 | 99 | ns | ns | 29/19 | ns | 1–60 | ns | 9 |
| Topal et al., 2007 [ | Belgium | 2003–2006 | Retrospective comparative | EGC, AGC | TG | 38 | 22 | 68 | 69 | 23/15 | 17/5 | 12 | 12 | 7 |
| Sarela et al., 2009 [ | UK | 2005–2007 | Retrospective comparative | EGC, AGC | SG | 18 | 11 | ns | ns | ns | ns | ns | Ns | 8 |
| Strong et al., 2009 [ | USA | 2005–2008 | Retrospective case-matched | EGC, AGC | SG | 30 | 30 | 71 | 73 | 13/17 | 14/16 | 36 | 36 | 7 |
| Orsenigo et al., 2011 [ | Italy | 2002–2008 | Retrospective comparative | EGC, AGC | SG | 109 | 269 | 66.57 | 66.73 | 56/53 | 169/100 | 33 | 33 | 8 |
| Scatizzi et al., 2011 [ | Italy | 2006–2009 | Retrospective comparative | EGC, AGC | SG | 30 | 30 | 70 | 69 | 16/14 | 14/16 | 18 | 18 | 8 |
| Sica et al., | Italy | 2000–2004 | Retrospective comparative | EGC, AGC | SG | 22 | 25 | 67 | 68 | 13/9 | 13/12 | 39 | 38 | 8 |
| Moisan et al., 2011 [ | Chile | 2003–2010 | Retrospective case-matched | EGC, AGC | SG, TG | 31 | 31 | 67 | 67 | 21/10 | 20/11 | 28 | 40 | 8 |
| MacLellan et al., 2012 [ | Canada | 2000–2009 | Retrospective comparative | EGC, AGC | SG, TG | 21 | 182 | 61 | 57 | 15/6 | 113/69 | 21.3 | ns | 7 |
| Singh et al., 2012 [ | UK | 2003–2010 | Prospective comparative | ns | SG, TG | 72 | 57 | ns | ns | ns | ns | ns | ns | 6 |
| Cianchi et al., 2013 [ | Italy | 2008–2012 | Prospective case-matched | EGC, AGC | SG, TG | 41 | 41 | 73 | 74 | 25/16 | 25/16 | ns | ns | 6 |
| Mamidanna et al., 2013 [ | UK | 2000–2010 | Retrospective comparative | EGC, AGC | SG, TG | 427 | 4329 | ns | ns | 276/204 | 6781/ 3502 | ns | ns | 8 |
| Kelly et al., 2015 [ | USA | 2005–2013 | Retrospective case-matched | EGC, AGC | SG, TG | 87 | 87 | 64 | 64 | 37/50 | 54/33 | 11 | 31.1 | 6 |
| Ramagem et al., 2015 [ | Brazil | 2009–2013 | Retrospective comparative | EGC, AGC | TG | 47 | 64 | 58 | 60 | 34/13 | 43/21 | ns | ns | 8 |
| Castro et al., 2016 [ | Portugal | 2010–2014 | Prospective comparative | ns | SG, TG | 63 | 144 | ns | ns | ns | ns | 29 | 29 | 7 |
| Malik et al., 2016 [ | UK | 2003–2014 | Retrospective comparative | ns | SG, TG | 114 | 161 | 73 | 72 | 55/56 | 101/48 | 60 | 60 | 7 |
| Brenkman | Netherlands | 2010–2014 | Retrospective comparative | EGC, AGC | SG, TG | 277 | 1663 | 68.5 | 68.4 | 173/104 | 1035/ | 12 | 12 | 8 |
| Tegels et al., 2017 [ | Netherlands | 2013–2014 | Retrospective + prospective comparative | EGC, AGC | SG, TG | 52 | 25 | 68 | 70 | 32/20 | 17/8 | ns | ns | 7 |
| Abbassi-Ghadi et al., 2018 [ | UK | 2006–2016 | Retrospective comparative | EGC, AGC | SG, TG | 35 | 44 | 77 | 71 | 21/14 | 35/9 | 60 | 60 | 8 |
| Ludwig et al., 2018 [ | Germany | 2013–2016 | Prospective case-control | EGC, AGC | SG, TG | 45 | 45 | 61.1 | 64.8 | 26/19 | 26/19 | 31 | 31 | 8 |
| Rod et al., 2018 [ | France | 2005–2015 | Retrospective comparative | EGC, AGC | SG, TG | 60 | 104 | 62 | 65 | 37/23 | 63/41 | ns | ns | 8 |
| Maida et al., 2019 [ | Italy | 2009–2013 | Retrospective case-matched | EGC, AGC | SG, TG | 60 | 67 | 71 | 67 | 28/32 | 36/31 | ns | ns | 8 |
| Raakow | Germany | 2005–2017 | Retrospective case-matched | EGC, AGC | SG, TG | 81 | 162 | 64.7 | 64.2 | 58/23 | 116/46 | ns | ns | 9 |
| Garbarino | Italy | 2009–2014 | Retrospective case-matched | AGC | SG | 34 | 34 | 70.9 | 71.1 | 23/11 | 21/13 | 31 | 31 | 8 |
| Tsekrekos et al., 2020 [ | Sweden | 2010–2018 | Retrospective comparative | EGC, AGC | SG, TG | 77 | 129 | 69 | 68 | 47/30 | 77/52 | ns | ns | 9 |
| Salehi et al., 2020 [ | USA | 2010–2016 | Retrospective comparative | EGC, AGC | SG, TG | 3170 | 10368 | 67.9 | 68.1 | 2162/ | 6814/ | ns | ns | 9 |
| Yalav et al., 2020 [ | Turkey | 2015–2018 | Retrospective comparative | EGC, AGC | TG | 18 | 89 | 57.3 | 59.4 | 12/6 | 58/31 | 25 | 15 | 8 |
| Ammori et al., 2020 [ | Jordan | 2017–2019 | Retrospective case-matched | EGC, AGC | SG, TG | 18 | 18 | 60.5 | 57.5 | 12/6 | 13/5 | ns | ns | 8 |
| van der Veen et al., 2021 [ | Netherlands | 2015–2018 | Randomized trial | EGC, AGC | SG, TG | 115 | 112 | 67.9 | 66.9 | 68/47 | 72/40 | 12 | 12 | 4 * |
| Ramos et al., 2021 [ | Brazil | 2009–2019 | Retrospective case-matched | EGC, AGC | SG, TG | 92 | 92 | ns | ns | 50/42 | 49/43 | 31 | 31 | 8 |
| van der Wielen et al., 2021 [ | Netherlands | 2015–2018 | Randomized trial | EGC, AGC | TG | 47 | 49 | 59.4 | 61.8 | 28/19 | 32/17 | 12 | 12 | 4 * |
*: Jadad scale for randomized trials, EGC: Early Gastric Cancer, AGC: Advanced gastric Cancer, SG: Sub-total Gastrectomy, TG: Total Gastrectomy, ns: non specified.
Figure 2Forest plots of (a) Operative Time; (b) Blood Loss; (c) Lymph Node Yield.
Figure 3Funnel plots of (a) Operative time; (b) Blood Loss; (c) Lymph Node Yield; (d) Analgesic Requirement; (e) Time to First Flatus; (f) Time to First Oral Intake; (g) Overall Morbidity; (h) Major Complications; (i) Length of Stay; (j) Mortality; (k) 3-year Overall Survival; (l) 5-year Overall Survival.
Table of complications of studies included in the meta-analysis.
| Author Year | Total | Complications | Grading of | Mortality | Readmissions | Reoperations | Duodenal Stump Leak | Anastomotic Leak | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LG | OG | LG | OG | LG | OG | LG | OG | LG | OG | LG | OG | LG | OG | LG | OG | ||
| Weber et al., 2003 [ | 12 | 13 | ns | ns | ns | ns | ns | ns | ns | ns | ns | ns | ns | ns | ns | ns | |
| Dulucq et al., 2005 [ | SG | 16 | 17 | 2 | 3 | C.D. I/II 1 | C.D. I/II 3 | 0 | 1 | ns | ns | 1 | 0 | 1 | 0 | 0 | 0 |
| TG | 8 | 11 | 0 | 1 | C.D. I/II 0 | C.D. I/II 1 | 0 | 0 | ns | ns | 0 | 0 | 0 | 0 | 0 | 0 | |
| Huscher et al., 2005 [ | 30 | 29 | 7 | 8 | C.D. I/II 7 | C.D. I/II 7 | 1 | 2 | ns | ns | ns | ns | 0 | 1 | 0 | 0 | |
| Pugliese et al., 2007 [ | 48 | 99 | 10 | 14 | ns | ns | 2 | 3 | ns | ns | 0 | 0 | 2 | 1 | 0 | 2 | |
| Topal et al., 2007 [ | 38 | 22 | 15 | 9 | TOSGS I/II 6 | TOSGS I/II 6 | 1 | 1 | ns | ns | 6 | 0 | 0 | 0 | 2 | 0 | |
| Sarela et al., 2009 [ | 18 | 11 | ns | ns | ns | ns | 1 | 1 | ns | ns | 3 | 2 | 3 | 1 | 1 | 0 | |
| Strong et al., 2009 [ | 30 | 30 | 8 | 13 | C.D. I/II 6 | C.D. I/II 6 | ns | ns | ns | ns | ns | ns | 0 | 0 | 0 | 1 | |
| Orsenigo et al., 2011 [ | 109 | 269 | 30 | 52 | ns | ns | 3 | 4 | ns | ns | 11 | 6 | 20 | 14 | ns | ns | |
| Scatizzi et al., 2011 [ | 30 | 30 | 2 | 8 | TOSGS I/II 2 | TOSGS I/II 6 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 2 | 0 | |
| Sica et al., | 22 | 25 | ns | ns | ns | ns | ns | ns | ns | ns | ns | ns | ns | ns | ns | ns | |
| Moisan et al., 2012 [ | 31 | 31 | 8 | 6 | ns | ns | ns | ns | ns | ns | 4 | 4 | 2 | 0 | 2 | 2 | |
| MacLellan et al., 2012 [ | 21 | 182 | ns | ns | ns | ns | ns | ns | ns | ns | ns | ns | ns | ns | ns | ns | |
| Singh et al., 2012 [ | 72 | 57 | 32 | 18 | ns | ns | 4 | 2 | ns | ns | ns | ns | ns | ns | ns | ns | |
| Cianchi et al., 2013 [ | 41 | 41 | 9 | 14 | ns | ns | 1 | 2 | ns | ns | 3 | 2 | 2 | 2 | 0 | 2 | |
| Mamidanna et al., 2013 [ | 480 | 10233 | 208 | 2661 | ns | ns | 23 | 571 | 58 | 1044 | 22 | 409 | ns | ns | ns | ns | |
| Kelly et al., 2015 [ | 87 | 87 | 27 | 42 | C.D. I/II 11 | C.D. I/II 26 | 1 | 0 | ns | ns | ns | ns | 6 | 4 | 4 | 4 | |
| Ramagen et al., 2015 [ | 47 | 64 | 4 | 13 | ns | ns | 1 | 2 | 2 | 3 | 3 | 4 | ns | ns | 1 | 3 | |
| Castro et al., 2016 [ | 63 | 144 | 8 | 35 | ns | ns | 1 | 9 | ns | ns | ns | ns | ns | ns | ns | ns | |
| Malik et al., 2016 [ | 114 | 161 | 31 | 48 | ns | ns | 5 | 5 | ns | ns | ns | ns | ns | ns | ns | ns | |
| Brenkman | 277 | 1663 | ns | ns | ns | ns | 13 | 79 | ns | ns | ns | ns | ns | ns | ns | ns | |
| Tegels et al., 2017 [ | 52 | 25 | 16 | 15 | C.D. I/II 10 | C.D. I/II 8 | 1 | 1 | 6 | 4 | ns | ns | ns | ns | 2 | 10 | |
| Abbassi-Ghadi et al., 2018 [ | 35 | 44 | 35 | 47 | C.D. I/II 30 | C.D. I/II 45 | 0 | 0 | 3 | 1 | 3 | 1 | ns | ns | 0 | 1 | |
| Ludwig et al., 2018 [ | 45 | 45 | 10 | 20 | C.D. I/II 6 | C.D. I/II 17 | 0 | 0 | ns | ns | 1 | 1 | 1 | 1 | 1 | 1 | |
| Rod et al., 2018 [ | 60 | 104 | 34 | 48 | C.D. I/II 10 | C.D. I/II 25 | 0 | 3 | ns | ns | 16 | 6 | 8 | 10 | 10 | 10 | |
| Maida et al., 2019 [ | 60 | 67 | 2 | 8 | C.D. I/II 1 | C.D. I/II 7 | 0 | 0 | ns | ns | 1 | 0 | 0 | 1 | ns | 0 | |
| Raakow et al., 2019 [ | 81 | 162 | 22 | 64 | C.D. I/II 4 | C.D. I/II 16 | 2 | 3 | ns | ns | 5 | 22 | 1 | 1 | 4 | 9 | |
| Garbarino | 31 | 34 | 7 | 11 | C.D. I/II 5 | C.D. I/II 5 | 1 | 0 | ns | ns | 2 | 6 | 2 | 3 | 1 | 1 | |
| Tsekrekos et al., 2020 [ | 77 | 129 | 49 | 88 | C.D. I/II 37 | C.D. I/II 46 | 0 | 3 | ns | ns | ns | ns | ns | ns | 1 | 18 | |
| Salehi et al., 2020 [ | 3170 | 10368 | ns | ns | ns | ns | 78 | 397 | 205 | 791 | ns | ns | ns | ns | ns | ns | |
| Yalav et al., 2020 [ | 18 | 89 | 7 | 18 | C.D. I/II ns | C.D. I/II ns | 0 | 10 | 3 | 18 | ns | ns | 2 | 3 | 2 | 4 | |
| Ammori et al., 2020 [ | 18 | 18 | 3 | 4 | ns | ns | 0 | 0 | 0 | 1 | 1 | 0 | ns | ns | ns | ns | |
| Van der Veen et al., 2021 [ | 115 | 112 | 50 | 46 | C.D. I/II 31 | C.D. I/II 21 | 12 | 10 | 11 | 10 | ns | ns | ns | ns | 10 | 11 | |
| Ramos et al., 2021 [ | 92 | 92 | ns | ns | C.D. I/II ns | C.D. I/II ns | 6 | 4 | ns | ns | ns | ns | ns | ns | ns | ns | |
| Van der Wielen et al., 2021 [ | 47 | 49 | 16 | 21 | C.D. I/II 8 | C.D. I/II 15 | 0 | 2 | ns | ns | 1 | 2 | ns | ns | 4 | 5 | |
Figure 4Forest plots of (a) Analgesic Requirement; (b) Time to First Flatus; (c) Time to First Oral Intake; (d) Overall Morbidity; (e) Major Complications; (f) Length of Stay; (g) Mortality.
Figure 5Forest plots of (a) 3-year Overall Survival; (b) 5-year Overall Survival.